X4 Pharmaceuticals (XFOR) Cash & Equivalents (2017 - 2025)

X4 Pharmaceuticals has reported Cash & Equivalents for 9 years, with the latest figure at $217.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 289.68% year-over-year to $217.0 million; the trailing twelve-month figure through Dec 2025 stood at $217.0 million (up 289.68% YoY), and the FY2025 full-year result was $217.0 million, up 289.68% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $217.0 million, up from $69.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $217.0 million in Q4 2025, with the low at $39.2 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $93.6 million across 5 years, with a median of $87.6 million in 2021.
• The largest YoY upside for Cash & Equivalents was 289.68% in 2025 against a maximum downside of 73.36% in 2025.
• X4 Pharmaceuticals' Cash & Equivalents stood at $81.8 million in 2021, then soared by 48.82% to $121.7 million in 2022, then fell by 18.49% to $99.2 million in 2023, then tumbled by 43.86% to $55.7 million in 2024, then jumped by 289.68% to $217.0 million in 2025.
• The last three Cash & Equivalents figures came in at $217.0 million (Q4 2025), $69.6 million (Q3 2025), and $39.2 million (Q2 2025), per Business Quant data.